STOCK TITAN

Cocrystal Pharma Inc - COCP STOCK NEWS

Welcome to our dedicated news page for Cocrystal Pharma (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cocrystal Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cocrystal Pharma's position in the market.

Rhea-AI Summary
Cocrystal Pharma announces dosing of first subjects in Phase 1 trial for CDI-988, a pan-norovirus and pan-coronavirus inhibitor. CDI-988 shows potent antiviral activity and favorable pharmacokinetics. Potential to save lives and reduce severity of infections. Transformational year ahead for Cocrystal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
-
Rhea-AI Summary
Cocrystal Pharma to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.27%
Tags
conferences
-
Rhea-AI Summary
Cocrystal Pharma, Inc. (Nasdaq: COCP) reported financial results for the three and six months ended June 30, 2023, and provided updates on its antiviral pipeline, upcoming milestones, and business activities. The company is on track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza A. It has also selected the novel protease inhibitor CDI-988 as the development lead in the oral norovirus program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.39%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.95%
Tags
none
Cocrystal Pharma Inc

Nasdaq:COCP

COCP Rankings

COCP Stock Data

14.75M
7.11M
30.03%
6.72%
0.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bothell

About COCP

cocrystal (otcqb:cocp) is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. cocrystal employs unique technologies and nobel prize winning expertise to create first- and best-in-class antiviral drugs. these technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. the company has identified promising, preclinical stage antiviral compounds for the unmet medical needs including hepatitis, influenza and norovirus infections. cocrystal has previously received strategic investments from teva pharmaceuticals, opko health (opk), dr. raymond schinazi, brace pharmaceutical, llc, and the frost group.